ARPA-H taps 7 teams for up to $160M to build bespoke gene editing drugs, betting on Baby KJ's playbook — but some scientists say funding falls short.
July 9, 2026 03:20 PM EDT
R&DCell/Gene Tx
ARPA-H bookmarks $160M for custom gene editing treatments. Is it enough?
Ryan Cross
Senior Science Correspondent
An ARPA-H program to jump-start custom gene editing treatments was delayed by a change in administrations. Now seven labs will…
The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival…
Children's Hospital of Philadelphia Secures Five-year, up to $38.9 Million ARPA‑H Award to Advance Personalized Gene Editing…
Early last year, startup iECURE’s experimental gene therapy seemingly cured a baby of a life-threatening genetic disease. But new…
ARPA-H launches bespoke gene therapy push, Lilly and Novo to promote Bridge program, and more biotech news from The Readout
The use of genome editing in early embryos has pulled back the curtain on the role of one of the key genes that orchestrates the…
